The AJMC® Pulmonary Arterial Hypertension compendium is a comprehensive resource for clinical news and expert insights for the progressive disorder, which is characterized by high blood pressure in the arteries that go from the heart to the lungs.
March 14th 2025
Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ranges from 4% to 28%, according to studies from the US and Europe—and that the prevalence of these comorbid condition is on the rise.
December 30th 2024
Ensuring a Path of Success for Drug Repurposing in PAH
January 14th 2021Among the viewpoints offered by the authors to overcome barriers in solving unmet needs in pulmonary arterial hypertension (PAH) are preclinical pipelines for drug repurposing, working around challenges in early-stage trial design, and refining target selection and demonstration of engagement.
Read More
Researchers Identify Predictors of Pulmonary Hypertension Among Patients With MPNs
December 29th 2020Survival among patients with myeloproliferative neoplasm (MPN)–associated pulmonary hypertension (PH) is generally short, although the true prevalence of PH among these patients is poorly understood.
Read More
Studies Highlight Multiple Underlying Etiologies of PAH, Predictive Factors of PAA
December 10th 2020A group of researchers published their research on the various underlying etiologies of pulmonary arterial hypertension (PAH), as well as predictive factors of pulmonary artery aneurysms (PAAs).
Read More
A Look at the Use of Echocardiography to Assess Macitentan Effects, Predict Mortality in PAH
December 5th 2020Two studies presented at CHEST 2020 assessed the impact of macitentan on cardiac function in pulmonary arterial hypertension (PAH) and determined what role reproducible exercise echocardiographic parameters have in predicting survival.
Read More
Selexipag Improves Outcomes in Patients With CTD-PAH
December 3rd 2020Use of selexipag in patients with connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH) resulted in outcomes similar to those seen in patients with idiopathic PAH, despite the traditionally poorer prognosis of CTD-PAH.
Read More
Risk of Death Differs for Elderly Patients With PAH Taking Endothelin Receptor Antagonists
November 20th 2020The mortality risk differs for the 3 endothelin receptor antagonists approved to treat pulmonary arterial hypertension (PAH) in elderly patients; however, a direct comparison in a controlled trial is still needed to confirm results.
Read More